AMENDMENT # 4 TO THE RESEARCH, OPTION AND LICENSE AGREEMENT DATED DECEMBER 7, 2001Research, Option and License Agreement • March 29th, 2002 • Vical Inc • Biological products, (no disgnostic substances)
AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Amendment # 5Research, Option and License Agreement • March 31st, 2003 • Vical Inc • Biological products, (no disgnostic substances)
This Amendment, dated this 23rd day of September, 2002, is by and between Œ VICAL INCORPORATED, a Delaware Corporation (“VICAL”), having a place of business located at 9373 Towne Centre Drive, Suite 100, San Diego, California 91212, USA, AVENTIS PASTEUR, a French Société Anonyme (“AvP”), having a registered head office located at 2 avenue Pont Pasteur, 69007 Lyon, France, and Ž AVENTIS PASTEUR Limited, a company organized and existing under the laws of the Province of Ontario, Canada (“AvP-Canada”) and having its principal place of business at Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4.
Confidential Treatment Requested by BIND Therapeutics, Inc. THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • December 17th, 2015 • BIND Therapeutics, Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of December 8, 2015 (the “Third Amendment Effective Date”), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) (“BIND”) and Pfizer Inc. (“Pfizer”) and amends that certain Research, Option and License Agreement between BIND Biosciences, Inc. and Pfizer, dated as of March 25, 2013 (the “Agreement”) and amended and restated as of June 12, 2013 and March 31, 2015. Capitalized terms used herein without definition herein shall have the meaning given such terms in the Agreement.
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED...Research, Option and License Agreement • June 9th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
This RESEARCH, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of April 15, 2015 (the “Effective Date”) by and between INTEC PHARMA LTD., with offices located at 12 Hartom St., P.O.B 45219, Jerusalem 91450 (“Intec Pharma”) and “[***]” with offices located at “[***]”, Massachusetts, “[***]” USA “[***]”. Each of Intec Pharma and “[***]” is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • December 23rd, 2015 • Clearside Biomedical, Inc. • Pharmaceutical preparations • Delaware
This Research, Option and License Agreement (hereinafter “Agreement”), effective as of April 27, 2015 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Clearside Biomedical, Inc., a Delaware corporation with corporate offices at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA 30005 (“Clearside”) (each, a “Party” and collectively, the “Parties”).
Confidential Treatment Requested by BIND Therapeutics, Inc. SECOND AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • May 7th, 2015 • BIND Therapeutics, Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of March 31, 2015 (the “Second Amendment Effective Date”), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) (“BIND”) and Pfizer Inc. (“Pfizer”) and amends that certain Research, Option and License Agreement between BIND Biosciences, Inc. and Pfizer, dated as of March 25, 2013 (the “Agreement”) and amended and restated as of June 12, 2013. Capitalized terms used herein without definition herein shall have the meaning given such terms in the Agreement.
